US2013274232A1PendingUtilityA1

Pharmaceutical Compositions

52
Assignee: MALHOTRA GEENAPriority: Jul 16, 2010Filed: Jul 18, 2011Published: Oct 17, 2013
Est. expiryJul 16, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:Geena MalhotraShrinivas Madhukar PurandareAmar Lulla
A61P 29/00A61P 11/00A61P 11/08A61P 11/06A61K 31/46A61K 9/0075A61K 31/4709A61K 31/58A61K 31/4704A61K 31/137A61K 9/008A61K 45/06A61K 2300/00A61K 31/167A61K 31/138A61K 31/439
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A pharmaceutical composition for inhalation comprising R(+) budesonide and one bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising R(+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients. 
     
     
         2 . A pharmaceutical composition according to  claim 1 , wherein R(+) budesonide in an amount ranging from 80-640 mcg. 
     
     
         3 . A pharmaceutical composition according to  claim 1 , wherein the bronchodilator comprises one or more beta 2 -agonists. 
     
     
         4 . A pharmaceutical composition according to  claim 3 , wherein the beta 2 -agonist is selected from albuterol, levoalbuterol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol, bitolterol mesylate, ritodrine, salmeterol, formoterol, arformoterol, carmoterol, bambuterol, clenbuterol, indacaterol, milveterol, vilanterol, olodaterol or a combination thereof. 
     
     
         5 . A pharmaceutical composition according to  claim 3 , wherein the beta 2 -agonist comprises formoterol. 
     
     
         6 . A pharmaceutical composition according to  claim 3 , wherein the beta 2 -agonist comprises arformoterol. 
     
     
         7 . A pharmaceutical composition according to  claim 3 , wherein the beta 2 -agonist comprises salmeterol. 
     
     
         8 . A pharmaceutical composition according to  claim 3 , wherein the beta 2 -agonist comprises carmoterol. 
     
     
         9 . A pharmaceutical composition according to  claim 3 , wherein carmoterol is in an amount ranging from 1 mcg-4 mcg. 
     
     
         10 . A pharmaceutical composition according to  claim 3 , wherein the beta 2 -agonist comprises indacaterol. 
     
     
         11 . A pharmaceutical composition according to  claim 3 , wherein indacaterol is in an amount ranging from 50 mcg-800 mcg. 
     
     
         12 . A pharmaceutical composition according to  claim 1 , wherein the bronchodilator comprises one or more anticholinergics. 
     
     
         13 . A pharmaceutical composition according to  claim 12 , wherein the anticholinergic is selected from tiotropium, ipratropium, oxitropium and combinations thereof. 
     
     
         14 . A pharmaceutical composition according to  claim 12 , wherein the anticholinergic comprises tiotropium. 
     
     
         15 . A pharmaceutical composition according to  claim 12 , wherein tiotropium is in an amount ranging from 9 mcg-18 mcg. 
     
     
         16 . A pharmaceutical composition according to  claim 12 , wherein the anticholinergic comprises oxitropium. 
     
     
         17 . A pharmaceutical composition according to  claim 12 , wherein the anticholinergic comprises ipratropium. 
     
     
         18 . A pharmaceutical composition according to  claim 1 , wherein the bronchodilator comprises one or more beta 2 -agonists and/or one or more anticholinergics. 
     
     
         19 . A pharmaceutical composition according to  claim 1 , comprising R(+) budesonide and formoterol . 
     
     
         20 . A pharmaceutical composition according to  claim 1 , comprising R(+) budesonide and arformoterol 
     
     
         21 . A pharmaceutical composition according to  claim 1 , comprising R(+) budesonide, tiotropium and carmoterol. 
     
     
         22 . A pharmaceutical composition according to  claim 1 , comprising R(+) budesonide, tiotropium and indacaterol. 
     
     
         23 . A pharmaceutical composition according to  claim 1 , wherein R(+) budesonide and beta 2 -agonists along with any excipients are formulated in a single pharmaceutical composition. 
     
     
         24 . A pharmaceutical composition according to  claim 1 , wherein R(+) budesonide and anticholinergics along with any excipients are formulated in a single pharmaceutical composition. 
     
     
         25 . A pharmaceutical composition according to  claim 1 , wherein beta 2 -agonists and anticholinergics along with any excipients are formulated in a single pharmaceutical composition. 
     
     
         26 . A pharmaceutical composition according to  claim 1 , wherein R(+) budesonide, beta 2 -agonists and anticholinergics along with any excipients are formulated in a single pharmaceutical composition. 
     
     
         27 . A pharmaceutical composition according to  claim 1 , formulated as an inhalation composition. 
     
     
         28 . A pharmaceutical composition according to  claim 1 , formulated for use in a metered dose inhaler. 
     
     
         29 . A pharmaceutical composition according to  claim 27 , further comprising a propellant. 
     
     
         30 . A pharmaceutical composition according to  claim 27 , further comprising an excipient selected from a cosolvent, an antioxidant, a surfactant, a bulking agent and a lubricant. 
     
     
         31 . A pharmaceutical composition according to  claim 1 , formulated for use as a dry powder inhalation formulation. 
     
     
         32 . A pharmaceutical composition according to  claim 31 , further comprising at least one finely divided pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulations. 
     
     
         33 . A combination composition according to  claim 32 , wherein said carrier includes a saccharide and/or a sugar alcohol. 
     
     
         34 . A combination composition according to  claim 1 , formulated for use as an inhalation solution. 
     
     
         35 . A combination composition according to  claim 34 , further comprising an excipient selected from a wetting agent, osmotic agent, a pH regulator, a buffering agent and a complexing agent, provided in a pharmaceutically acceptable vehicle. 
     
     
         36 . A pharmaceutical composition according to  claim 1 , formulated for inhalation, for use as a nasal spray, for use as nasal drops, for use as an insufflation powder, or for use as a spray patch. 
     
     
         37 . A pharmaceutical composition according to  claim 1 , for once daily administration. 
     
     
         38 . A pharmaceutical composition according to  claim 1  , further comprising one or more active(s) selected from antihistamines, antiallergics or leukotriene antagonist or their pharmaceutically acceptable salts, solvates, tautomers, derivatives, enantiomers, isomers, hydrates, prodrugs or polymorphs thereof. 
     
     
         39 . A process for manufacturing a pharmaceutical composition according to  claim 1 , comprising combining R(+) budesonide with one or more bronchodilators and one or more optional pharmaceutically acceptable excipients. 
     
     
         40 . (canceled) 
     
     
         41 . (canceled) 
     
     
         42 . (canceled) 
     
     
         43 . (canceled) 
     
     
         44 . A method of prophylaxis or treatment of a respiratory, inflammatory or obstructive airway disease, comprising administering a therapeutically effective amount of a pharmaceutical composition according to  claim 1 , to a patient in need thereof. 
     
     
         45 . A method according to  claim 44 , wherein said pharmaceutical composition is administered once daily. 
     
     
         46 . A method according to  claim 44 , wherein the disease is COPD or asthma. 
     
     
         47 . (canceled) 
     
     
         48 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.